NCT02719613 2026-04-15
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
Phase 2 Completed
Clinical Trials
43 trialsNCT03984097 2026-04-09
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Phase 1 Completed
NCT01592370 2025-10-22
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04045795 2025-09-12
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Sanofi
Phase 1 Completed
NCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT06163040 2025-07-31
A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT01946477 2025-06-06
POM MM 014
Celgene
Phase 2 Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT03288974 2025-04-15
Pomalyst PMS
Celgene
Completed
NCT02555839 2025-03-28
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Celgene
Completed
NCT03269136 2025-03-18
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
Pfizer
Phase 1 Completed
NCT02990338 2025-01-17
ICARIA-MM
Sanofi
Phase 3 Completed
NCT02939183 2024-09-26
INTREPID-1
Amgen
Phase 1 Completed
NCT02616640 2024-09-19
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT03257631 2024-04-16
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Celgene
Phase 2 Completed
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT01734928 2023-06-06
OPTIMISMM
Celgene
Phase 3 Completed
NCT02726581 2023-03-27
CheckMate 602
Bristol-Myers Squibb
Phase 3 Completed
NCT03439280 2023-02-24
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Takeda
Phase 1/2 Completed
NCT01575925 2022-11-04
POM Renal
Celgene
Phase 1 Completed
NCT02654132 2022-11-01
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Bristol-Myers Squibb
Phase 2 Completed
NCT02164955 2022-10-20
A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
Celgene
Completed
NCT01712789 2022-01-10
STRATUS
Celgene
Phase 3 Completed
NCT01421186 2021-11-16
A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma
MorphoSys AG
Phase 1/2 Completed
NCT02045017 2021-08-27
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
Celgene
Phase 2 Completed
NCT02283775 2021-07-09
PomdeSAR
Sanofi
Phase 1 Completed
NCT02612779 2021-07-02
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Bristol-Myers Squibb
Phase 2 Completed
NCT02431208 2021-04-02
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Hoffmann-La Roche
Phase 1 Completed
NCT01497093 2020-04-07
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT02189343 2019-11-21
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT00463385 2019-11-20
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
Celgene
Phase 2 Completed
NCT01324947 2019-11-19
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Celgene
Phase 3 Completed
NCT01568294 2019-11-12
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT01178281 2019-07-17
RESUME
Celgene
Phase 3 Completed
NCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed
NCT01311687 2018-10-24
NIMBUS
Celgene
Phase 3 Completed
NCT02071888 2018-07-18
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT03424928 2018-02-07
A Pilot Bioequivalence Study of Pomalidomide
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02103335 2017-11-22
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT02011113 2016-11-01
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
Celgene Corporation
Phase 2 Completed
NCT00833833 2016-04-27
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
Celgene Corporation
Phase 1/2 Completed
NCT00072722 2006-12-19
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
Celgene
Phase 2 Completed